Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20362277 | 0.85 | TSHR (0.46) | TSHRCYP3A4ALDH1A1S1PR4MAPT | |
| SCHEMBL4034840 | 0.85 | TSHR (0.60) | TSHRCYP3A4ALDH1A1KAT2BS1PR4 | |
| SCHEMBL7193090 | 0.85 | TSHR (0.64) | TSHRCYP3A4ALDH1A1KAT2BACHE | |
| SCHEMBL27599498 | 0.83 | TSHR (0.62) | TSHRCYP3A4ALDH1A1KAT2BS1PR4 | |
| SCHEMBL6907821 | 0.81 | TSHR (0.60) | TSHRCYP3A4ALDH1A1KAT2BACHE | |
| SCHEMBL68019 | 0.81 | TSHR (0.60) | TSHRCYP3A4ALDH1A1KAT2BACHE | |
| SCHEMBL29137475 | 0.81 | TSHR (0.60) | TSHRCYP3A4ALDH1A1KAT2BS1PR4 | |
| SCHEMBL16976285 | 0.81 | TSHR (0.60) | TSHRCYP3A4ALDH1A1KAT2BS1PR4 | |
| SCHEMBL31672310 | 0.81 | TSHR (0.60) | TSHRCYP3A4ALDH1A1KAT2BACHE | |
| SCHEMBL67997 | 0.81 | TSHR (0.60) | TSHRCYP3A4ALDH1A1KAT2BS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400166-A2 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| EP-3565484-B1 | COMPOSITIONS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | CONTRALINE INC (US) | 2024-04-03 | — | — | EP | claimed |
| EP-3565484-A1 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. (US) | 2019-11-13 | — | — | EP | claimed |
| WO-2018129369-A1 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. (US) | 2018-07-12 | — | — | WO | claimed |
| US-20180185096-A1 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. | 2018-07-05 | — | — | US | claimed |
| US-12383421-B2 | Contraceptive devices | Contraline, Inc. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2025-07-03 | — | — | US | disclosed |
| CN-115066428-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4400166-A2 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2024-04-04 | — | — | US | disclosed |
| EP-3565484-B1 | COMPOSITIONS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | CONTRALINE INC (US) | 2024-04-03 | — | — | EP | disclosed |
| CN-114029091-B | Dual ligand catalytic system for ethylene selective trimerization, preparation method and application thereof | 浙江智英石化技术有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-1994027954-A1 | NITROBENZYL MUSTARD QUATERNARY SALTS AND THEIR USE AS HYPOXIA-SELECTIVE CYTOTOXIC AGENTS | AUCKLAND UNISERVICES LIMITED (NZ) | 1994-12-08 | — | — | WO | disclosed |
| CN-1016175-B | Imidazoquinoline antithrombin cardiotonic agents | BRISTOL MYERS CO (US) | 1992-04-08 | — | — | CN | disclosed |
| EP-0261503-A1 | Heterocyclic amido derivatives of substituted benzoic acids and therapeutic compositions which contain them as active principle | VALEAS S.p.A. INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 1988-03-30 | — | — | EP | disclosed |
| US-4668686-A | 1,3-DIHYDRO-2H-IMIDAZO/4,5-B/QUINOLINE-2-ONES | BRISTOL-MYERS COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
| CN-86102747-A | The preparation method of imidazoquinoline antithombogehic cardiotonic agents | — | 1987-02-04 | — | — | CN | disclosed |
| US-4495101-A | Antiinflammatory 5H-tetrazolo (5,1-c)(1,4)benzodiazepine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-01-22 | — | — | US | disclosed |
| US-4372956-A | CARDIOTONIC AGENTS, VASODILATION | SANDOZ LTD. (CH) | 1983-02-08 | — | — | US | disclosed |
| EP-0029559-A2 | 5,10-dihydroimidazo(2,1-b)quinazolines, their production and pharmaceutical compositions containing them | SANDOZ AG (CH) | 1981-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | TSHR 282/4885CYP3A4 4458/4885ALDH1A1 1427/4885 |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | TSHR 282/4885CYP3A4 4458/4885ALDH1A1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.